Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIMITLESS: Exablate BBBO in NSCLC Brain Metastases
NCT05317858Phase 3Recruiting
- Sponsor
- Insightec
- Start
- Aug 2022
- Primary completion
- Jun 2031
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in brain metastases and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Insightec. Primary endpoints: Adverse events at 6 months and Objective Response Rate at 6 months. Started Aug 2022; status: recruiting.
02
Conditions
brain metastasesnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05317858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317858.